国元证券给予药康生物买入评级，2023年半年度报告点评：研发投入继续加大，明星项目持续推进

七印授权

26NJRDZ7AKRPBCZ1WATF1TTLDKRFK8HB8Z9U4XO8WDG51N1LKV

2023-09-06 09:46:54

article

061EA9DC5C9C8256B99718E731B7847D911AED135A8E067141BD0ECECFF6600B

zh-CN

810C6AC3DBE42EC737C2BFAC2D1B6C124E284D4A

15203703

02636d79fc7c7cc37b9cb348037eec28743d030e5d570d0d69837a3587bed31880

9f4f1be5ba66f24285e799953025a4cd5c88e9d4f8201f3f7144ad099f218b970e3f6d2458f141433621473348a486cdc843b5332f7db9497de9d2551175cfec1c

{"parameters":{"adaptation":"n","price":"100000"},"type":"cm"}

yuanben_64f84a8e53c726.02558779

原本认证

https://www.yuanben.io/article/6849bd5e-001d-420c-9441-31a9603d48d1

{"author":"每日经济新闻","authorization_pub_key":"03040cbbeae1adf91c3efd7306d09c6005403a041f9b7405dac489d4f8126fef8c"}